April 1, 2013
BioLife Solutions (OTC: BLFS) Q4/12 and FY12 Results – STRONG BUY
March 22, 2013
Cytori (CYTX) updating the legal ruling
February 28, 2013
Harvard Bio (HBIO) Q4/12 and FY12 Results
February 4, 2013
Stem Cell Therapeutics (TSX VENTURE: SSS) Merger with Trillium Therapeutics and 1 for 10 reverse
February 1, 2013
Stemline Therapeutics (STML) Closes IPO and overallotment
January 7, 2013
BioLife Solutions (BIO: BLFS) Reports Preliminary 2012 Revenue at $5.7 M;
December 12, 2012
NeoStem (NYSE MKT: NBS), The nexus between curative regeneration and personalized medicine
December 7, 2012
Cytomedix (OTC QX: CMXI) Veterinary application for equine endometritis (PMIE)
November 14, 2012
NeoStem (NYSE MKT: NBS) Q3/12 Achievements and Highlights and Results
November 8, 2012
Cytomedix (OTCQX: CMXI) ANGEL® cPRP System granted FDA 510(K) Clearance for processing Blood and Bone Marrow Aspirate
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.